Cancer Research AACR Membership Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, K.-W.
Right arrow Articles by Russell, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, K.-W.
Right arrow Articles by Russell, S. J.
[Cancer Research 62, 4656-4662, August 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus1

Kah-Whye Peng2, Cynthia J. TenEyck, Evanthia Galanis, Kimberly R. Kalli, Lynn C. Hartmann and Stephen J. Russell

Molecular Medicine Program [K-W. P., C. J. T., S. J. R.], Medical Oncology [E. G., L. C. H.], and Endocrine Research Unit [K. R. K.], Mayo Clinic, Rochester, Minnesota 55905

The use of replicating viruses for cancer therapy (virotherapy) holds much promise.We reported previously that the live attenuated Edmonston B vaccine strain of measles virus (MV-Edm) had antineoplastic efficacy against hematological malignancies. In this study, we demonstrate that a recombinant MV-Edm, genetically engineered to express an inert soluble marker peptide (MV-hCEA), is potent against human epithelial ovarian cancer cells in vitro and in vivo. The virus was selectively oncolytic for ovarian tumor cells but caused minimal cytopathic damage on nontransformed ovarian surface epithelium and mesothelium. In contrast to nontransformed cells, the ovarian tumor cells expressed high levels of the measles virus receptor CD46. When injected directly into large established s.c. SKOV3ip.1 human epithelial ovarian xenografts in athymic mice, the virus induced complete regression of 80% of the tumors. i.p. administration of virus enhanced the median survival of mice with advanced i.p. SKOV3ip.1 tumors by >50 days. In addition, we could easily follow the kinetic profile of viral gene expression in the treated mice by determining serum levels of the virally encoded marker peptide (soluble human carcinoembryonic antigen). Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer.




This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
S. K. Carlson, K. L. Classic, E. M. Hadac, D. Dingli, C. E. Bender, B. J. Kemp, and S. J. Russell
Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene
Am. J. Roentgenol., January 1, 2009; 192(1): 279 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gauvrit, S. Brandler, C. Sapede-Peroz, N. Boisgerault, F. Tangy, and M. Gregoire
Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response
Cancer Res., June 15, 2008; 68(12): 4882 - 4892.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. Hasegawa, C. Hu, T. Nakamura, J. D. Marks, S. J. Russell, and K.-W. Peng
Affinity Thresholds for Membrane Fusion Triggering by Viral Glycoproteins
J. Virol., December 1, 2007; 81(23): 13149 - 13157.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann
Current Management Strategies for Ovarian Cancer
Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, M. Figini, S. Canevari, L. C. Hartmann, and K.-W. Peng
The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6170 - 6178.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
I. D. Iankov, M. Pandey, M. Harvey, G. E. Griesmann, M. J. Federspiel, and S. J. Russell
Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.
J. Virol., September 1, 2006; 80(17): 8530 - 8540.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J.V. Vaha-Koskela, J. P. Kallio, L. C. Jansson, J. E. Heikkila, V. A. Zakhartchenko, M. A. Kallajoki, V.-M. Kahari, and A. E. Hinkkanen
Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
Cancer Res., July 15, 2006; 66(14): 7185 - 7194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Hasegawa, L. Pham, M. K. O'Connor, M. J. Federspiel, S. J. Russell, and K.-W. Peng
Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Clin. Cancer Res., March 15, 2006; 12(6): 1868 - 1875.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
D. M. Duelli, S. Hearn, M. P. Myers, and Y. Lazebnik
A primate virus generates transformed human cells by fusion
J. Cell Biol., November 7, 2005; 171(3): 493 - 503.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
S. J. Russell
Measles Virus: A Potent, Versatile, Retargetable Oncolytic Platform
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 389 - 394.
[Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Kitagawa, H. Tani, C. K. Limn, T. M. Matsunaga, K. Moriishi, and Y. Matsuura
Ligand-Directed Gene Targeting to Mammalian Cells by Pseudotype Baculoviruses
J. Virol., March 15, 2005; 79(6): 3639 - 3652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. D. Anderson, T. Nakamura, S. J. Russell, and K.-W. Peng
High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus
Cancer Res., July 15, 2004; 64(14): 4919 - 4926.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Dingli, K.-W. Peng, M. E. Harvey, P. R. Greipp, M. K. O'Connor, R. Cattaneo, J. C. Morris, and S. J. Russell
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
Blood, March 1, 2004; 103(5): 1641 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Vongpunsawad, N. Oezgun, W. Braun, and R. Cattaneo
Selectively Receptor-Blind Measles Viruses: Identification of Residues Necessary for SLAM- or CD46-Induced Fusion and Their Localization on a New Hemagglutinin Structural Model
J. Virol., January 1, 2004; 78(1): 302 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Grote, R. Cattaneo, and A. K. Fielding
Neutrophils Contribute to the Measles Virus-induced Antitumor Effect: Enhancement by Granulocyte Macrophage Colony-stimulating Factor Expression
Cancer Res., October 1, 2003; 63(19): 6463 - 6468.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. K. Phuong, C. Allen, K.-W. Peng, C. Giannini, S. Greiner, C. J. TenEyck, P. K. Mishra, S. I. Macura, S. J. Russell, and E. C. Galanis
Use of a Vaccine Strain of Measles Virus Genetically Engineered to Produce Carcinoembryonic Antigen as a Novel Therapeutic Agent against Glioblastoma Multiforme
Cancer Res., May 15, 2003; 63(10): 2462 - 2469.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K.-W. Peng, K. A. Donovan, U. Schneider, R. Cattaneo, J. A. Lust, and S. J. Russell
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker
Blood, April 1, 2003; 101(7): 2557 - 2562.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.